Your browser doesn't support javascript.
loading
Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care.
Shiffman, Dov; Louie, Judy Z; Devlin, James J; Knowles, Joshua W; McPhaul, Michael J.
Affiliation
  • Shiffman D; Quest Diagnostics Nichols Institute San Juan Capistrano CA.
  • Louie JZ; Quest Diagnostics Nichols Institute San Juan Capistrano CA.
  • Devlin JJ; Quest Diagnostics Nichols Institute San Juan Capistrano CA.
  • Knowles JW; Stanford Cardiovascular Medicine and Cardiovascular Institute and the FH Foundation Stanford CA.
  • McPhaul MJ; Quest Diagnostics Nichols Institute San Juan Capistrano CA.
J Am Heart Assoc ; 9(9): e015807, 2020 05 05.
Article in En | MEDLINE | ID: mdl-32319337
ABSTRACT
Background The American Heart Association and American College of Cardiology guidelines defined patient-management groups that would benefit from lowering of low-density lipoprotein cholesterol (LDL-C). We assessed gaps in dyslipidemia care among employees and spouses with health benefits. Methods and Results We studied 17 889 employees and spouses who were covered by an employer-sponsored health plan and participated in an annual health assessment. Using medical claims, laboratory tests, and risk assessment questionnaires, we found that 43% of participants were in one of 4 patient-management groups secondary prevention, severe hypercholesterolemia (LDL-C ≥190 mg/dL at least once in the preceding 5 years), diabetes mellitus, or elevated 10-year risk of cardiovascular disease. To assess gaps in dyslipidemia care, we used LDL-C ≤70 mg/dL as the goal for both the secondary prevention group and those in the elevated 10-year risk group with >20% risk; LDL-C ≤100 mg/dL was used for the other groups. Among those in patient-management groups, 27.3% were in the secondary prevention group, 7.4% were in the severe hypercholesterolemia group, 29.9% were in the diabetes mellitus group, and 35.4% were in the elevated 10-year risk group. About 74% of those in patient-management groups had above-goal LDL-C levels, whereas only 31% had evidence of a lipid-lowering therapy in the past 6 months 45% in the secondary prevention group, 31% in the severe hypercholesterolemia group, 36% in the diabetes mellitus group, and 17% in the elevated 10-year risk group. Conclusions The substantial gaps in LDL-C treatment and goal attainment among members of an employer-sponsored medical plan who were mostly aware of their LDL-C levels indicate the need for gap-closure initiatives.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Occupational Health / Dyslipidemias / Professional Practice Gaps / Health Benefit Plans, Employee / Cholesterol, LDL / Anticholesteremic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: J Am Heart Assoc Year: 2020 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiovascular Diseases / Occupational Health / Dyslipidemias / Professional Practice Gaps / Health Benefit Plans, Employee / Cholesterol, LDL / Anticholesteremic Agents Type of study: Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: J Am Heart Assoc Year: 2020 Type: Article